Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.
angiogenesis
biomarker
glioblastoma
magnetic resonance imaging
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Jan 2019
14 Jan 2019
Historique:
received:
27
10
2018
revised:
17
12
2018
accepted:
20
12
2018
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
17
1
2019
Statut:
epublish
Résumé
A higher degree of angiogenesis is associated with shortened survival in glioblastoma. Feasible morphometric parameters for analyzing vascular networks in brain tumors in clinical practice are lacking. We investigated whether the macrovascular network classified by the number of vessel-like structures (nVS) visible on three-dimensional T1-weighted contrast⁻enhanced (3D-T1CE) magnetic resonance imaging (MRI) could improve survival prediction models for newly diagnosed glioblastoma based on clinical and other imaging features. Ninety-seven consecutive patients (62 men; mean age, 58 ± 15 years) with histologically proven glioblastoma underwent 1.5T-MRI, including anatomical, diffusion-weighted, dynamic susceptibility contrast perfusion, and 3D-T1CE sequences after 0.1 mmol/kg gadobutrol. We assessed nVS related to the tumor on 1-mm isovoxel 3D-T1CE images, and relative cerebral blood volume, relative cerebral flow volume (rCBF), delay mean time, and apparent diffusion coefficient in volumes of interest for contrast-enhancing lesion (CEL), non-CEL, and contralateral normal-appearing white matter. We also assessed Visually Accessible Rembrandt Images scoring system features. We used ROC curves to determine the cutoff for nVS and univariate and multivariate cox proportional hazards regression for overall survival. Prognostic factors were evaluated by Kaplan-Meier survival and ROC analyses. Lesions with nVS > 5 were classified as having highly developed macrovascular network; 58 (60.4%) tumors had highly developed macrovascular network. Patients with highly developed macrovascular network were older, had higher volume
Identifiants
pubmed: 30646519
pii: cancers11010084
doi: 10.3390/cancers11010084
pmc: PMC6356693
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundació La Marato TV3
ID : 665/C/2013
Références
Cancer Res. 1999 Nov 15;59(22):5830-5
pubmed: 10582706
Bull Acad Natl Med. 2000;184(3):557-67
pubmed: 10989552
J Neurooncol. 2000 Oct-Nov;50(1-2):165-72
pubmed: 11245275
Nat Med. 2001 Sep;7(9):987-9
pubmed: 11533692
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66
pubmed: 11849564
AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1767-74
pubmed: 12427637
Brain Pathol. 2003 Apr;13(2):133-43
pubmed: 12744467
IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71
pubmed: 12956271
Cancer Treat Res. 2004;117:79-95
pubmed: 15015553
Am J Clin Pathol. 2004 Nov;122(5):675-7
pubmed: 15491962
Histopathology. 2005 May;46(5):481-9
pubmed: 15842629
AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74
pubmed: 16286386
AJNR Am J Neuroradiol. 2006 Apr;27(4):853-8
pubmed: 16611778
Cancer. 2006 Jul 1;107(1):162-70
pubmed: 16721804
NMR Biomed. 2006 Jun;19(4):463-75
pubmed: 16763973
Neuroimage. 2007;37 Suppl 1:S116-9
pubmed: 17512217
Phys Med. 2008 Jun;24(2):87-91
pubmed: 18294894
AJNR Am J Neuroradiol. 2008 Sep;29(8):1505-10
pubmed: 18556364
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Surg Neurol. 2009 Sep;72(3):242-6; discussion 246-7
pubmed: 19329156
Oncology. 2009;77(1):1-11
pubmed: 19439998
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
J Neurosurg. 2010 May;112(5):997-1004
pubmed: 19817542
Radiology. 2010 May;255(2):622-8
pubmed: 20413772
J Clin Oncol. 2010 Aug 20;28(24):3838-43
pubmed: 20644085
Microvasc Res. 2010 Dec;80(3):522-33
pubmed: 20888350
AJNR Am J Neuroradiol. 2011 Feb;32(2):388-94
pubmed: 21071537
Brain Tumor Pathol. 2012 Apr;29(2):73-86
pubmed: 22218709
Cancer. 2012 Nov 15;118(22):5595-600
pubmed: 22517216
PLoS One. 2012;7(8):e41522
pubmed: 22870228
Clin Neuropathol. 2012 Sep-Oct;31(5):342-51
pubmed: 22939175
Eur Radiol. 2013 Apr;23(4):1093-101
pubmed: 23085863
Neuro Oncol. 2013 Jan;15(1):91-6
pubmed: 23095230
Radiology. 2013 Apr;267(1):212-20
pubmed: 23238158
Radiology. 2013 May;267(2):560-9
pubmed: 23392431
Neuro Oncol. 2013 Oct;15(10):1389-94
pubmed: 23396489
Clin Drug Investig. 2013 Apr;33(4):303-14
pubmed: 23435930
Acad Radiol. 2013 Apr;20(4):478-85
pubmed: 23498990
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
Acta Neurochir (Wien). 2014 Apr;156(4):641-51
pubmed: 24553726
Radiology. 2014 Aug;272(2):484-93
pubmed: 24646147
Radiat Oncol. 2014 Apr 23;9:95
pubmed: 24758192
Neuro Oncol. 2015 Aug;17(8):1139-47
pubmed: 25754089
Transl Oncol. 2015 Jun;8(3):137-46
pubmed: 26055170
AJNR Am J Neuroradiol. 2015 Nov;36(11):2030-5
pubmed: 26206809
J Clin Neurosci. 2015 Nov;22(11):1802-8
pubmed: 26308396
Neuroradiology. 2016 Jan;58(1):17-26
pubmed: 26438560
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):765-779
pubmed: 27742116
Eur J Radiol. 2017 Feb;87:120-124
pubmed: 28034567
Contrast Media Mol Imaging. 2017 Mar 20;2017:7064120
pubmed: 29097933
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
Semin Roentgenol. 2018 Jan;53(1):23-36
pubmed: 29405952
Br J Radiol. 1993 Mar;66(783):181-96
pubmed: 7682469
Radiology. 1994 Apr;191(1):41-51
pubmed: 8134596
Cancer. 1996 Jan 15;77(2):362-72
pubmed: 8625246
J Neurooncol. 1996 Jan;27(1):65-73
pubmed: 8699228
Acta Neurol Scand. 1998 Jan;97(1):52-62
pubmed: 9482679
J Neurosurg. 1998 Mar;88(3):513-20
pubmed: 9488306
Hum Pathol. 1998 Apr;29(4):352-8
pubmed: 9563784
Acta Radiol. 1998 May;39(3):227-32
pubmed: 9571934
AJR Am J Roentgenol. 1998 Dec;171(6):1479-86
pubmed: 9843274